Sequenom Reports 20 Percent Increase in Q1 Revenues | GenomeWeb

NEW YORK (GenomeWeb) – Sequenom reported after the close of the market Thursday that its first quarter revenues climbed 20 percent compared to the first quarter of 2013, driven by its diagnostics business, including sales of its MaterniT21 Plus noninvasive prenatal test for fetal aneuploidy.

The San Diego-based molecular diagnostics firm reported total Q1 revenues of $46.3 million, compared to $38.5 million in the first quarter 2013. Revenues were slightly above the Wall Street consensus estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.